FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231140383> ?p ?o ?g. }

• W4231140383 abstract "Background Human albumin solutions are used in a range of medical and surgical problems. Licensed indications are the emergency treatment of shock and other conditions where restoration of blood volume is urgent, burns, and hypoproteinaemia. Human albumin solutions are more expensive than other colloids and crystalloids. Objectives To quantify the effect on mortality of human albumin and plasma protein fraction (PPF) administration in the management of critically ill patients. Search methods We searched the Cochrane Injuries Group trials register, CENTRAL (The Cochrane Library issue 2, 2008), MEDLINE, EMBASE, BIDS Index to Scientific and Technical Proceedings, ISI Web of Knowledge: Science Citation Index, Zetoc. Reference lists of trials and review articles were checked, and authors of identified trials were contacted. The search was last updated in June 2008. Selection criteria Randomised controlled trials comparing albumin/PPF with no albumin/PPF, or with a crystalloid solution, in critically ill patients with hypovolaemia, burns or hypoalbuminaemia. Data collection and analysis We collected data on the participants, albumin solution used, mortality at the end of follow up, and quality of allocation concealment. Analysis was stratified according to patient type. Main results We found 37 trials meeting the inclusion criteria and reporting death as an outcome. There were 1686 deaths among 8716 trial participants. For hypovolaemia, the relative risk of death following albumin administration was 1.01 (95% confidence interval 0.93 to 1.11). This estimate was heavily influenced by the results of the SAFE trial which contributed 88.2% of the information (based on the weights in the meta‐analysis). For burns, the relative risk was 2.52 (1.22 to 5.22) and for hypoalbuminaemia the relative risk was 1.20 (0.87 to 1.64). There was no substantial heterogeneity between the trials in the various categories (chi‐square = 25.25, df = 30, p = 0.71). The pooled relative risk of death with albumin administration was 1.04 (0.96 to 1.13). Authors' conclusions For patients with hypovolaemia, there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia. The possibility that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question. However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to alternatives such as saline, it would seem reasonable that albumin should only be used within the context of well concealed and adequately powered randomised controlled trials." @default.
• W4231140383 created "2022-05-11" @default.
• W4231140383 date "2004-10-18" @default.
• W4231140383 modified "2023-10-18" @default.
• W4231140383 title "Human albumin solution for resuscitation and volume expansion in critically ill patients" @default.
• W4231140383 cites W1533841935 @default.
• W4231140383 cites W1554783366 @default.
• W4231140383 cites W1966407782 @default.
• W4231140383 cites W1979237902 @default.
• W4231140383 cites W1982388235 @default.
• W4231140383 cites W1984933612 @default.
• W4231140383 cites W1986656594 @default.
• W4231140383 cites W1991471243 @default.
• W4231140383 cites W1992071990 @default.
• W4231140383 cites W1994257456 @default.
• W4231140383 cites W1995096417 @default.
• W4231140383 cites W2001590139 @default.
• W4231140383 cites W2002227327 @default.
• W4231140383 cites W2004657762 @default.
• W4231140383 cites W2005198956 @default.
• W4231140383 cites W2009643143 @default.
• W4231140383 cites W2011876586 @default.
• W4231140383 cites W2011932878 @default.
• W4231140383 cites W2012170541 @default.
• W4231140383 cites W2012594970 @default.
• W4231140383 cites W2014463376 @default.
• W4231140383 cites W2016889358 @default.
• W4231140383 cites W2019336636 @default.
• W4231140383 cites W2023914296 @default.
• W4231140383 cites W2029438444 @default.
• W4231140383 cites W2035140417 @default.
• W4231140383 cites W2035998090 @default.
• W4231140383 cites W2037301086 @default.
• W4231140383 cites W2040617042 @default.
• W4231140383 cites W2048245345 @default.
• W4231140383 cites W2055133170 @default.
• W4231140383 cites W2057698184 @default.
• W4231140383 cites W2058842482 @default.
• W4231140383 cites W2061965543 @default.
• W4231140383 cites W2065285118 @default.
• W4231140383 cites W2069035013 @default.
• W4231140383 cites W2070055633 @default.
• W4231140383 cites W2071998315 @default.
• W4231140383 cites W2073940375 @default.
• W4231140383 cites W2080942352 @default.
• W4231140383 cites W2081081088 @default.
• W4231140383 cites W2081317807 @default.
• W4231140383 cites W2089169276 @default.
• W4231140383 cites W2090119255 @default.
• W4231140383 cites W2092046515 @default.
• W4231140383 cites W2102412617 @default.
• W4231140383 cites W2113586719 @default.
• W4231140383 cites W2126639731 @default.
• W4231140383 cites W2127062066 @default.
• W4231140383 cites W2141510885 @default.
• W4231140383 cites W2143432233 @default.
• W4231140383 cites W2150563200 @default.
• W4231140383 cites W2154601847 @default.
• W4231140383 cites W2156187328 @default.
• W4231140383 cites W2157823046 @default.
• W4231140383 cites W2425406154 @default.
• W4231140383 cites W2897650666 @default.
• W4231140383 cites W2986772077 @default.
• W4231140383 cites W4242882997 @default.
• W4231140383 cites W4292824565 @default.
• W4231140383 cites W4294553798 @default.
• W4231140383 doi "https://doi.org/10.1002/14651858.cd001208.pub2" @default.
• W4231140383 hasPublicationYear "2004" @default.
• W4231140383 type Work @default.
• W4231140383 citedByCount "19" @default.
• W4231140383 countsByYear W42311403832013 @default.
• W4231140383 countsByYear W42311403832019 @default.
• W4231140383 countsByYear W42311403832020 @default.
• W4231140383 countsByYear W42311403832021 @default.
• W4231140383 countsByYear W42311403832022 @default.
• W4231140383 countsByYear W42311403832023 @default.
• W4231140383 crossrefType "reference-entry" @default.
• W4231140383 hasBestOaLocation W42311403832 @default.
• W4231140383 hasConcept C126322002 @default.
• W4231140383 hasConcept C177713679 @default.
• W4231140383 hasConcept C194828623 @default.
• W4231140383 hasConcept C2776125364 @default.
• W4231140383 hasConcept C2776478404 @default.
• W4231140383 hasConcept C2778165595 @default.
• W4231140383 hasConcept C3019038604 @default.
• W4231140383 hasConcept C44249647 @default.
• W4231140383 hasConcept C535046627 @default.
• W4231140383 hasConcept C71924100 @default.
• W4231140383 hasConcept C82789193 @default.
• W4231140383 hasConcept C95190672 @default.
• W4231140383 hasConceptScore W4231140383C126322002 @default.
• W4231140383 hasConceptScore W4231140383C177713679 @default.
• W4231140383 hasConceptScore W4231140383C194828623 @default.
• W4231140383 hasConceptScore W4231140383C2776125364 @default.
• W4231140383 hasConceptScore W4231140383C2776478404 @default.
• W4231140383 hasConceptScore W4231140383C2778165595 @default.
• W4231140383 hasConceptScore W4231140383C3019038604 @default.
• W4231140383 hasConceptScore W4231140383C44249647 @default.
• W4231140383 hasConceptScore W4231140383C535046627 @default.
• W4231140383 hasConceptScore W4231140383C71924100 @default.

• next